Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 3/2009

01-12-2009 | Short communication

Tailored targeted therapy for all: a realistic and worthwhile objective against

Author: Kathleen I Pritchard

Published in: Breast Cancer Research | Special Issue 3/2009

Login to get access

Excerpt

Targeted therapy for breast cancer was actually used, albeit unwittingly, as early as the late 1800s. Beatson first surgically removed the ovaries of women to treat metastatic breast cancer in 1896 [1], while Schinzinger recommended ovarian irradiation as adjuvant therapy in 1889 [2]. Ovarian ablation and subsequently diethylstilbestrol were initially used to treat breast cancer without knowing the target to which they were directed. More than 50 years later Jensen and Jacobson discovered the oestrogen receptor (ER) [3], which was subsequently understood to be the target or partial target of these endocrine approaches. …
Literature
1.
Beatson GT: On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet. 1896, 2: 104-107. 10.1016/S0140-6736(01)72307-0.CrossRef
2.
Schinzinger A: Ueber carcinoma mammae. Verh Dtsch Ges Chir. 1889, 18: 28-29.
3.
Jensen EV, Jacobson HI: Fate of steroid estrogens in target tissues. Biological Activities of Steroids in Relation to Cancer. Edited by: Pincus G, Vollmer EP. 1960, New York: Academic Press, 161-178.CrossRef
4.
Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005, 365: 1687-1717. 10.1016/S0140-6736(05)66544-0.CrossRef
5.
Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet. 1998, 351: 1451-1467. 10.1016/S0140-6736(97)11423-4.CrossRef
6.
Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, Dimitrov NV, Wolmark N, Wickerham DL, Fisher ER, Margolese R, Robidoux A, Shibata H, Terz J, Paterson AHG, Feldman MI, Farrar W, Evans J, Lickley HL, Ketner M: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989, 320: 479-484. 10.1056/NEJM198902233200802.CrossRefPubMed
7.
Fisher B, Redmond C, Brown A, Fisher ER, Wolmark N, Bowman D, Plotkin D, Wolter J, Bornstein R, Legault-Poisson S: Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5 year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J Clin Oncol. 1986, 4: 459-471.PubMed
8.
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004, 351: 2817-2826. 10.1056/NEJMoa041588.CrossRefPubMed
9.
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Watson D, Bryant J, Costantino J, Wolmark N: Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer [meeting abstracts]. J Clin Oncol. 2005, 23: 510-
10.
Habel LA, Quesenberry CP, Jacobs MK, Blick NT, Greenberg D, Alexander C, Baker J, Walker M, Watson D, Shak S: A large case-controlled study of gene expression and breast cancer death in the North California Kaiser Permanente population [abstract 3019]. Breast Cancer Res Treat. 2004, 88: S118-
11.
Paik S, Shak S, Tang G, Kim C, Kim WK, Baker J, Cronin M, Walker M, Bryant J, Wolmark N: Risk classification of breast cancer patients by the recurrence score assay: comparison to guidelines based on patient age, tumor size and tumor grade [abstract 104]. Breast Cancer Res Treat. 2004, 88: S21-
12.
Mamounas E, Tang G, Bryant J, Paik S, Shak S, Costantino J, Watson D, Wickerham DL, Wolmark N: Association between 21-gene recurrence score assay and risk of locoregional failure in node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20 [abstract 29]. Breast Cancer Res Treat. 2005, 94: S16-
13.
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al: Studies of the Her-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989, 244: 707-712. 10.1126/science.2470152.CrossRefPubMed
14.
Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S, Pritzker KP, Hartwick RW, Hanna W, Lickley L, Wilkinson R, Qizilbash A, Ambus U, Lipa M, Weizel H, Katz A, Baida M, Mariz S, Stoik G, Dacamara P, Strongitharm D, Geddie W, McCready D: neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol. 1998, 16: 1340-1349.PubMed
15.
Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002, 22: 719-726. 10.1200/JCO.20.3.719.CrossRef
16.
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming TR, Eiermann W, Norton L, Wolter J, Pegram MD, Baselga J: Use of chemotherapy plus a monoclonal antibody against Her2 for metastatic breast cancer that overexpresses Her2. N Engl J Med. 2001, 344: 783-792. 10.1056/NEJM200103153441101.CrossRefPubMed
17.
Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson CJ, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H, Slamon DJ: Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst. 2003, 95: 142-153. 10.1093/jnci/95.2.142.CrossRefPubMed
18.
Ellis M: Overcoming endocrine therapy resistance by signal transduction inhibition. Oncologist. 2004, 9: 20-26. 10.1634/theoncologist.9-suppl_3-20.CrossRefPubMed
19.
De Laurentiis M, Arpino G, Massarelli E, Ruggiero A, Carlomagno C, et al: HER2 as predictive marker of resistance to endocrine treatment for advanced breast cancer: a meta-analysis of published studies [abstract 233]. Breast Cancer Res Treat. 2002, 76: S68-
20.
Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova A, Revil C, Jones A: Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol. 2009,
21.
Pritchard KI, Shepherd LE, O'Malley FP, Andrulis IL, Tu D, Bramwell VH, Levine M: HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med. 2006, 354: 2103-2111. 10.1056/NEJMoa054504.CrossRefPubMed
22.
Gennari A, Sormani M, Puntoni M: A pooled analysis on the interaction between Her-2 expression and responsiveness of breast cancer ot adjuvant chemotherapy [abstract 41]. Br Cancer Res Treat. 2006, 100: 19-
23.
Bartlett JMS, Munro A, Cameron DA, Thomas J, Prescott R, Twelves C: Type I receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. J Clin Oncol. 2008, 26: 5027-5035. 10.1200/JCO.2007.14.6597.CrossRefPubMed
24.
O'Malley F, Chia S, Tu D, Shepherd L, Levine M, Bramwell V, Andrulis I, Pritchard KI: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst. 2009, 101: 644-650. 10.1093/jnci/djp067.CrossRefPubMedPubMedCentral
25.
Pritchard KI, Messersmith H, Elavathil L, Trudeau M, O'Malley F, Dhesy-Thind B: Her-2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol. 2008, 26: 1-9. 10.1200/JCO.2007.14.5920.CrossRef
26.
Di Leo A, Isola J, Piette F, Ejlertsen B, Pritchard KI, Bartlett JMS, Desmedt C, Larsimont D, Tanner M, Mouridsen H, O'Malley F, Twelves C, Cardoso F, Poole C, Piccart-Gebhart MJ, Buyse M: A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy [abstract 705]. Breast Cancer Res Treat. 2008, 107: 24-
27.
Reinholz MM, Jenkins RB, Hillman DW, Lingle W, Davidson NE, Martino S, Kaufman PA, Perez EA: The clinical significance of poly 17 in the HER2 and N98431 intergroup adjuvant trastuzumab trial [abstract 36]. Breast Cancer Res Treat. 2007, 107: S11-
28.
Bartlett JMS, Munro A, Dunn J, Hiller L, Jordan S, Twelves C, Cameron DA, Thomas J, Campbell F, Rea DW, Provenzano E, Pharoah PD, Caldas C, Earl H, Poole CJ: Chromosome 17 polysomy (CH17) as a predictor of anthracycline response: emerging evidence from the UK NEAT adjuvant breast cancer trial [abstract 45]. Breast Cancer Res Treat. 2008, 107: 20-
29.
Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007, 357: 2666-2676. 10.1056/NEJMoa072113.CrossRefPubMed
Metadata
Title
Tailored targeted therapy for all: a realistic and worthwhile objective against
Author
Kathleen I Pritchard
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 3/2009
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2427

Other articles of this Special Issue 3/2009

Breast Cancer Research 3/2009 Go to the issue

Short communication

Alcohol consumption and breast cancer risk

Short communication

Radiation impact in breast cancer

Section introduction

Debate: tailored targeted therapy for all - a realistic and worthwhile objective? Introduction to Session 2

Section introduction

The potential of new technologies/approaches. Introduction to Sessions 3 and 4

Short communication

The role of preclinical animal models in breast cancer drug development

Short communication

Clinical relevance and current challenges of research on disseminating tumor cells in cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits